Abstract
The Cutting Edge Jennifer Moriatis Wolf, MD; Kenneth L. Cameron, ATC, PhD; Kari B. Clifton, PhD; Brett D. Owens, MD Relaxin was originally described as a reproductive hormone that mediated joint laxity in pregnant women and has been minimally studied in men. The purpose of this descriptive laboratory and clinical study was to evaluate serum relaxin in a young, primarily male population and compare levels between the sexes. In addition, the authors evaluated the relationship between relaxin and generalized laxity. The authors are from the Department of Orthopaedic Surgery (JMW, KBC), University of Connecticut Health Center, Farmington, Connecticut; and the John A. Feagin Jr Sports Medicine Fellowship (KLC, BDO), Keller Army Hospital, United States Military Academy, West Point, New York. The authors have no relevant financial relationships to disclose. This study was supported by a Prospective Research Grant from the Orthopaedic Research and Education Foundation (BDO) and pilot funding from the Connecticut Institute of Clinical and Translational Science (Clinical Research Center Grant #M01RR006192) (JMW). The authors thank Pamela Fall, PhD, of the General Clinical Research Center for her assistance with this project. Correspondence should be addressed to: Jennifer Moriatis Wolf, MD, Department of Orthopaedic Surgery, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030-4037 (jmwolf@uchc.edu). Relaxin is a peptide hormone that was first described as a reproductive hormone produced in pregnancy, which acts to loosen pelvic ligaments and soften the cervix in preparation for parturition.1 Relaxin is also produced in nonpregnant women2 and has been shown to have multiple physiologic effects in humans, including improvement of cardiac and renal blood flow through vasodilation3 and prevention of lung fibrosis.4 In the musculoskeletal system, relaxin’s role in ligamentous laxity has been investigated in the anterior cruciate ligament (ACL) and anterior oblique ligament of the basilar thumb joint.5,6 Relaxin secretion has also been demonstrated in men’s reproductive tracts.7 Relaxin has a key influence on prostate growth and development.8 Relaxin receptors have also been shown in the ACLs of men, although less consistently than in women.9 In a study of 9 men and 5 women (mean age, 58 years) with congestive heart failure, serum relaxin levels averaged 20 pg/mL, which was approximately 12-fold lower in age-matched controls.10 Although normative levels of relaxin have been investigated in pregnant and non-pregnant women,2,11 limited data exist on normative serum relaxin levels in men. The majority of reported serum relaxin levels in men are derived from studies of patients with renal or cardiac failure and may be reflective of the effect of chronic disease on this multidimensional hormone. No studies to date have evaluated serum relaxin levels in a cohort of young and physically active men. The purpose of this study was to evaluate serum relaxin in a large population of young athletic men and to compare serum relaxin levels and the proportion with detectable levels between the sexes. A secondary objective was to evaluate the relationship between relaxin and generalized joint laxity. For this descriptive laboratory and clinical study, the authors obtained serum samples that were derived from blood collected for administrative testing during the admissions process for a military academy. Inclusion criteria included age 18 years or older and willingness to participate by signing informed consent. Military cadets are chosen through a rigorous screening process that emphasizes academic excellence, physical fitness and endurance, and the desire to ultimately serve in the military. On entrance, they undergo extensive physical, mental, and academic testing, and the authors obtained serum from blood drawn during this process. Blood from 857 men and 135 women was collected during the standard intake physical in the summer of 2006. In addition, a subset of this group was examined during the intake examination using the Beighton-Horan criteria to determine generalized laxity.12 This study was reviewed and approved by the Keller Army Hospital institutional review board. Levels of human relaxin-2, the circulating form of relaxin, were determined using enzyme-linked immunosor-bent assay (ELISA) sandwich testing (Quantikine Human Relaxin-2 Immunoassay; R&D Systems, Minneapolis, Minnesota). All testing was performed in accordance with the manufacturer’s protocol. Assays were performed in duplicate. Results were determined from the standard curve, extrapolated to 0. The mean minimum detectable dose of this kit is 1 pg/mL (range, 0.26–4.54 pg/mL). The authors evaluated the primary outcome of interest—serum relaxin levels—similar to the methods used by Dragoo et al.6 First, 0 values were assigned to all participants who had a serum sample available for analysis but had no detectable serum relaxin values when the sample was analyzed by ELISA. Subsequently, a similar subgroup analysis was performed that included only those participants with detectable serum relaxin levels, defined as a serum relaxin level of 1 pg/mL or more. Means and SDs were calculated for continuous variables, and frequencies and proportions were...

This publication has 21 references indexed in Scilit: